Intensified myeloablative therapy and autologous stem-cell transplantation for patients with AML: Single center experience

Cytotherapy

Volumn 5, Issue 2, 2003, Pages 139-146

  Novitzky, Nicholas ^a,b   Thomas, V ^a,b   Stubbings, H ^a,b  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

Acute myelogenous leukemia; Autologous stem cell transplantation; Radiotherapy

Indexed keywords

ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; MESNA; MORPHINE SULFATE; OFLOXACIN; RETINOIC ACID;

ABDOMINAL DISTENSION; ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; APHERESIS; ARTICLE; AUTOTRANSPLANTATION; BLOOD VOLUME; BONE MARROW SUPPRESSION; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; COLONY FORMING UNIT GM; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRYOPRESERVATION; DEATH; DIARRHEA; DRUG FEVER; DRUG TOXICITY; DYSPHAGIA; DYSPLASIA; FEMALE; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; GRAFT INFECTION; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER VEIN OBSTRUCTION; LYMPH NODE IRRADIATION; MALE; MUCOSA INFLAMMATION; MULTIMODALITY CANCER THERAPY; MULTIVARIATE ANALYSIS; PAIN; PERIPHERAL BLOOD STEM CELL; RADIATION DOSE FRACTIONATION; STEM CELL MOBILIZATION; STEM CELL TRANSPLANTATION; SURVIVAL TIME; THROMBOCYTE COUNT; THROMBOCYTE FUNCTION; WHOLE BODY RADIATION;

EID: 0038585036     PISSN: 14653249     EISSN: None     Source Type: Journal    
DOI: 10.1080/14653240310001037     Document Type: Article

References (31)

1. Preisler H, Davis RB, Kirshner J et al. Comparison of three remission induction regimens and two postinduction strategies for the treatment of acute nonlymphocytic leukemia: A cancer and leukemia group B study. Blood 1987;69:1441-9.
2. Preisler HD, Anderson K, Rai K. The frequency of long-term remission in patients with acute myeloid leukemia with conventional maintenance chemotherapy: A study of 760 patients with a minimum follow up time of six years. Br J Haematol 1989;71:189-94.
3. Bishop JF, Lowenthal RM, Joshua D et al. Etoposide in acute nonlymphocytic leukemia. Australian Leukemia Study Group. Blood 1990;75:27-32.
4. Beguin Y, Sautois B, Forget P et al. Long term follow up of patients with acute myelogenous leukemia who received the daunorubicin, vincristine and cytosine arabinoside regimen. Cancer 1997;79:1351-4.
5. Baudard M, Bauchaud-Nicod A, Delmer A et al. Has the prognosis of adult patients with acute myeloid leukemia improved over years? A single institution experience of 748 consecutive patients over 16-year period. Leukaemia 1999;13:1481-90.
6. Zittoun RA, Mandelli F, Willemze R et al. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups. N Engl J Med 1995;332:217-23.
7. Weisdorf D, Haake R, Blazar B et al. Treatment of moderate/severe acute graft-versus-host disease after allogeneic bone marrow transplantation: An analysis of clinical risk features and outcome. Blood 1990;75:1024-30.
8. Keating S, Suciu S, De Witte T et al. Prognostic factors of patients with acute myeloid leukemia (AML) allografted in first complete remission: An analysis of the EORTC-GIMEMA AML 8A trial. [The European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell' Adulto (GIMEMA) Leukemia Cooperative Groups]. Bone Marrow Transplant 1996;17:993-1001.
9. Conde E, Iriondo A, Rayon C et al. Allogeneic bone marrow transplantation versus intensification chemotherapy for acute myelogenous leukaemia in first remission: A prospective controlled trial. Br J Haematol 1988;68:219-26.
10. Thomas ED, Storb R, Clift RA et al. Bone-marrow transplantation [second of two parts]. N Engl J Med 1975;292:895-902.
11. Scarpati D, Frassoni F, Vitale V et al. Total body irradiation in acute myeloid leukemia and chronic myelogenous leukemia: Influence of dose and dose-rate on leukemia relapse. Int J Radiat Oncol Biol Phys 1989;17:547-52.
12. Weiden PL, Sullivan KM, Flournoy N et al. Antileukemic effect of chronic graft-versus-host disease: Contribution to improved survival after allogeneic marrow transplantation. N Engl J Med 1981;304:1529-33.
13. Novitzky N, Thomas V, Hale G, Waldmann H. Ex vivo T cell depletion of bone marrow grafts with CAMPATH 1 is an effective measure to prevent graft versus host disease without abrogating the antileukaemic effect of transplantation. Transplantation 1999;67:620-6.
14. Bennett JM, Catovsky D, Daniel MT et al. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol 1976;33:451-8.
15. Asou N, Adachi K, Tamura J et al. Analysis of prognostic factors in newly diagnosed acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Japan Adult Leukemia Study Group. J Clin Oncol 1998;16:78-85.
16. Vahdat L, Maslak P, Miller Jr WH et al. Early mortality and the retinoic acid syndrome in acute promyelocytic leukemia: Impact of leukocytosis, low-dose chemotherapy, PMN/RAR-alpha isoform, and CD13 expression in patients treated with all-trans retinoic acid. Blood 1994;84:3843-9.
17. Fenaux P, Chastang C, Chevret S et al. A randomized comparison of all trans retinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group. Blood 1999;94:1192-200.
18. Viniou NA, Yataganas X, Stamatopoulos K et al. Reverse transcription polymerase chain reaction for the diagnosis and molecular monitoring of the PML/RAR alpha fusion gene in acute promyelocytic leukemia. Cancer Gen Cytogen 1995;84:91-4.
19. Diverio D, Pandolfi PP, Rossi V et al. Monitoring of treatment outcome in acute promyelocytic leukemia by RT-PCR. Leukemia 1994;8:1105-7.
20. Huang ME, Ye YC, Chen SR et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988;72:567-72.
21. Fenaux P, Chastang C, Degos L. Treatment of newly diagnosed acute promyelocytic leukemia (APL) by a combination of all-trans retinoic acid (ATRA) and chemotherapy. French APL Group. Leukemia 1994;8(Suppl 2):42-7.
22. Degos L, Dombret H, Chomienne C et al. All-trans-retinoic acid as a differentiating agent in the treatment of acute promyelocytic leukemia. Blood 1995;85:2643-53.
23. Hickman RO, Buckner CD, Clift RA et al. A modified right atrial catheter for access to the venous system in marrow transplant recipients. Surg Gynecol Obstet 1979;148:871-5.
24. Jacobs P, Wood L, Horal S. Collection and cryopreservation of human stem and progenitor cells for the bone marrow transplantation. J Clin Apheresis 1991;6:54-8.
25. + cell determination by flow cytometry. J Hematother 1996;5:213-26.
26. Imrie K, Dicke K, Keating A. Autologous bone marrow transplantation for acute myeloid leukemia. Stem Cells 1996;14:69-78.
27. + cells for autologous stem cell transplantation significantly reduces febrile complications and use of antibiotics after transplantation. Bone Marrow Transplant 1999;23:1177-81.
28. Redner RL, Rush EA, Faas S et al. The t(5;17) variant of acute promyelocytic leukemia expresses a nucleophosmin-retinoic acid receptor fusion. Blood 1996;87:882-6.
29. Byrd JC, Dodge RK, Carroll A et al. Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered. J Clin Oncol 1999;17:3767-75.
30. Gorin NC. Autologous stem cell transplantation in acute myelocytic leukemia. Blood 1998;92:1073-90.
31. Hirst WJ, Mufti GJ. Clinical annotation. Management of myelodysplastic syndromes. Br J Haematol 1993;84:191-6.